We have located links that may give you full text access.
Journal Article
Review
Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.
Seminars in Oncology 2004 December
Several adjuvant trials evaluating aromatase inhibitors in postmenopausal women with early breast cancer have shown significant improvement upon, or extension of the efficacy benefits of, standard therapy with tamoxifen, and treatments were generally well tolerated. Disease-free survival was significantly improved by: anastrozole versus tamoxifen for 5 years of adjuvant therapy, in the Arimidex, Tamoxifen Alone or in Combination trial; switching to exemestane after 2 to 3 years of tamoxifen, compared with remaining on tamoxifen for 5 years, in the Intergroup Exemestane Study; and switching to letrozole (v placebo) for 5 years after 5 years of tamoxifen, in the extended adjuvant trial, MA.17. Further analyses of these trials, and data from ongoing trials, will address how to optimally use aromatase inhibitors in the adjuvant breast cancer setting: whether these agents should be used in place of, or sequenced with, tamoxifen; what is the best order of sequencing, before or after tamoxifen, and when is the best time to switch; what the long-term safety issues are associated with aromatase inhibitor treatment; and how toxicities can be effectively managed.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app